UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdicti ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|-------------------------------- ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2020 Results Conference Call May 6, 2020 4:30 PM ET Company Participants Eric Hyllengren - Investor Relations Pascal Touchon - President and Chief Executive Officer Utpal Koppikar - Chief Financial Officer Joe Newell - Chief Operations Officer A.J. Joshi - Chief Medical Officer Conference Call Participants Marc Frahm - Cowen and Company John Newman - Canaccord Genuity Salim Syed - Mizuho Securities Yigal Nochomovitz - Citigroup Tony Butler - Roth Capital Andrea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdiction o ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q4 2019 Results Earnings Conference Call February 27, 2020 8:00 AM ET Company Participants John Craighead - Vice President-Investor Relations and Corporate Communications Pascal Touchon - President and Chief Executive Officer AJ Joshi - Chief Medical Officer Joe Newell - Chief Operations Officer Conference Call Participants Phil Nadeau - Cowen & Company John Newman - Canaccord Matt Phipps - William Blair Salim Syed - Mizuho Securities Benjamin Burnett - Stifel Opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdic ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2019 Earnings Conference Call November 7, 2019 8:00 AM ET Company Participants John Craighead – Vice President-Investor Relations and Corporate Communications Pascal Touchon – President and Chief Executive Officer AJ Joshi – Chief Medical Officer Conference Call Participants Anupam Rama – JPMorgan John Newman – Canaccord Salim Syed – Mizuho Securities Phil Nadeau – Cowen and Company Tony Butler – Roth Capital Salveen Richter – Goldman Sachs Ben Burnett – Stifel M ...

[PART I. FINANCIAL INFORMATION](index=3&type=section&id=PART%20I.%20FINANCIAL%20INFORMATION) [Financial Statements (Unaudited)](index=3&type=section&id=Item%201.%20Financial%20Statements%20(Unaudited)) The company reported a Q3 2019 net loss of $71.9 million and held $282.9 million in cash and investments amid significant R&D spending [Condensed Consolidated Balance Sheets](index=3&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) Total assets were $364.8 million as of September 30, 2019, with total stockholders' equity at $318.4 million Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | Sep 30, 2019 | Dec 31, 2018 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $94,431 | $60,698 | | Short-term investments | $188,491 | $248,933 | | Total current assets | $293,418 | $321,489 | | Total assets | $364,785 | $391,839 | | **Liabilities & Equity** | | | | Total current liabilities | $30,706 | $39,979 | | Total liabilities | $46,343 | $52,982 | | Total stockholders' equity | $318,442 | $338,857 | | Total liabilities and stockholders' equity | $364,785 | $391,839 | [Condensed Consolidated Statements of Operations and Comprehensive Loss](index=4&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) The company's net loss increased to $71.9 million in Q3 2019, driven by higher research, development, and administrative expenses Statement of Operations Highlights (in thousands, except per share data) | Metric | Q3 2019 | Q3 2018 | Nine Months 2019 | Nine Months 2018 | | :--- | :--- | :--- | :--- | :--- | | Research and development | $53,538 | $43,355 | $154,457 | $105,202 | | General and administrative | $19,018 | $16,865 | $61,525 | $50,093 | | **Loss from operations** | **($72,556)** | **($60,220)** | **($215,982)** | **($155,295)** | | **Net loss** | **($71,895)** | **($58,361)** | **($212,480)** | **($150,687)** | | Net loss per share | ($1.31) | ($1.29) | ($4.32) | ($3.49) | [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) Net cash used in operations was $176.9 million for the nine-month period, offset by $151.3 million raised from financing activities Cash Flow Summary (Nine Months Ended Sep 30, in thousands) | Activity | 2019 | 2018 | | :--- | :--- | :--- | | Net cash used in operating activities | ($176,936) | ($122,353) | | Net cash provided by (used in) investing activities | $59,332 | ($242,357) | | Net cash provided by financing activities | $151,337 | $351,515 | | **Net increase (decrease) in cash** | **$33,733** | **($13,195)** | [Notes to Condensed Consolidated Financial Statements](index=7&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) Notes detail the company's operating losses, reliance on equity financing, and adoption of the new lease standard ASC 842 - Atara is a clinical-stage allogeneic T-cell immunotherapy company developing treatments for cancer, autoimmune, and viral diseases with an **accumulated deficit of $739.5 million** as of September 30, 2019[17](index=17&type=chunk)[19](index=19&type=chunk) - The company adopted the new lease accounting standard (ASU 2016-02, Topic 842) on January 1, 2019, recognizing **operating lease assets of $14.3 million** and liabilities of $15.3 million[33](index=33&type=chunk)[34](index=34&type=chunk) - In July 2019, the company raised **gross proceeds of $150.0 million** ($140.7 million net) through an underwritten public offering of common stock and pre-funded warrants[77](index=77&type=chunk) - The company utilizes an "at the market" (ATM) facility, selling 686,131 shares for **net proceeds of $12.6 million** during the first nine months of 2019[80](index=80&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=20&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses its focus on key T-cell programs, rising R&D costs, and its belief that cash is sufficient into 2021 - The company's strategic priorities are its most advanced T-cell immunotherapy programs: **Tab-cel® (Phase 3), ATA188, and next-generation CAR T programs**[98](index=98&type=chunk) - Atara plans to initiate a **Biologics License Application (BLA) submission for Tab-cel®** for patients with EBV+ PTLD in the second half of 2020[103](index=103&type=chunk) - The company expects its existing cash, cash equivalents, and short-term investments of **$282.9 million** (as of Sep 30, 2019) will be sufficient to fund planned operations into 2021[133](index=133&type=chunk)[141](index=141&type=chunk) Research & Development Expenses by Program (in thousands) | Program | Nine Months 2019 | Nine Months 2018 | Change | | :--- | :--- | :--- | :--- | | Tab-cel® expenses | $34,006 | $33,748 | $258 | | ATA188, ATA190, CAR T & other | $24,060 | $11,753 | $12,307 | | Employee and overhead | $96,391 | $59,701 | $36,690 | | **Total R&D Expenses** | **$154,457** | **$105,202** | **$49,255** | [Quantitative and Qualitative Disclosures about Market Risk](index=27&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20about%20Market%20Risk) The company reports no material changes to its market risk disclosures during the nine months ended September 30, 2019 - There were **no material changes** to the company's market risk disclosures, including interest rate and foreign currency exchange rate risks, during the nine months ended September 30, 2019[148](index=148&type=chunk) [Controls and Procedures](index=28&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded that disclosure controls and procedures were effective with no material changes to internal controls - The CEO and CFO concluded that the company's **disclosure controls and procedures were effective** as of September 30, 2019[150](index=150&type=chunk) - **No changes in internal control over financial reporting** occurred during the quarter that materially affected, or are reasonably likely to materially affect, the company's internal controls[153](index=153&type=chunk) [PART II. OTHER INFORMATION](index=29&type=section&id=PART%20II.%20OTHER%20INFORMATION) [Legal Proceedings](index=29&type=section&id=Item%201.%20Legal%20Proceedings) The company is not currently involved in any material legal proceedings - The company reports **no material legal proceedings**[155](index=155&type=chunk) [Risk Factors](index=29&type=section&id=Item%201A.%20Risk%20Factors) The company faces significant financial, developmental, manufacturing, commercialization, and intellectual property risks - **Financial Risks:** The company has a history of substantial losses (**$739.5 million accumulated deficit**) and expects to incur increasing losses, requiring substantial additional financing[158](index=158&type=chunk)[165](index=165&type=chunk) - **Development & Regulatory Risks:** Product candidates are in early development and represent new therapeutic approaches (allogeneic T-cell therapy), facing **heightened regulatory scrutiny and potential trial failures**[171](index=171&type=chunk)[181](index=181&type=chunk) - **Manufacturing & Supply Risks:** The company is subject to significant manufacturing risks, including process scale-up and **reliance on its ATOM facility and third-party CMOs**[223](index=223&type=chunk)[229](index=229&type=chunk)[237](index=237&type=chunk) - **Commercialization Risks:** Success depends on market acceptance, obtaining adequate reimbursement, and **competing with established therapies** and companies with greater resources[274](index=274&type=chunk)[276](index=276&type=chunk)[288](index=288&type=chunk) - **Intellectual Property Risks:** The company **relies heavily on in-licensed patents** and know-how from partners like MSK, and losing these rights could significantly harm the business[246](index=246&type=chunk)[266](index=266&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=62&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) The company reports no unregistered sales of equity securities during the period - None reported[343](index=343&type=chunk) [Defaults Upon Senior Securities](index=62&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) The company reports no defaults upon senior securities - None reported[343](index=343&type=chunk) [Mine Safety Disclosures](index=62&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company - Not applicable[344](index=344&type=chunk) [Other Information](index=62&type=section&id=Item%205.%20Other%20Information) The company reports no other information - None reported[344](index=344&type=chunk) [Exhibits](index=62&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including corporate documents and required certifications